Paltab Tablet 125 mg contains Palbociclib, an oral targeted therapy used in the treatment of hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer. Palbociclib belongs to a class of drugs known as CDK4/6 inhibitors, which work by interfering with proteins involved in cell cycle progression, effectively slowing the growth and proliferation of cancer cells.

Paltab is typically prescribed in combination with endocrine therapy, such as aromatase inhibitors or fulvestrant, to enhance its therapeutic effects. This combination approach is designed to provide a more effective, targeted treatment for patients with advanced breast cancer, delaying disease progression and improving overall outcomes.

The 125 mg tablet is the standard high-dose formulation for adult patients, allowing once-daily oral administration for ease of use and improved treatment adherence. Paltab provides a precise, consistent dosing regimen under oncologist supervision, making it an integral part of modern breast cancer therapy.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Key Features

• Contains Palbociclib 125 mg per tablet

• CDK4/6 inhibitor for targeted breast cancer therapy

• Effective for hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer

• Oral tablet for convenient once-daily dosing

• Used in combination with endocrine therapy for enhanced efficacy

• Helps slow cancer cell proliferation and disease progression

Indications

Paltab Tablet 125 mg is indicated for:

• Advanced or metastatic HR+, HER2-negative breast cancer in postmenopausal or premenopausal women (with ovarian suppression)

• Combination therapy with an aromatase inhibitor as initial endocrine-based treatment

• Combination therapy with fulvestrant in patients with disease progression following prior endocrine therapy

It is prescribed exclusively under oncologist supervision and requires regular monitoring to ensure safety and effectiveness.

Mechanism of Action

Palbociclib selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), which are crucial regulators of the cell cycle. Its mechanism includes:

• Blocking phosphorylation of the retinoblastoma protein (Rb)

• Preventing transition from the G1 phase to the S phase of the cell cycle

• Inhibiting cancer cell proliferation

• Enhancing the effectiveness of concurrent endocrine therapy

By targeting the cell cycle, Paltab reduces tumor growth while minimizing damage to normal cells, offering a more targeted and precise approach to cancer treatment.

Dosage and Administration

• Standard adult dose: 125 mg orally once daily for 21 consecutive days, followed by 7 days off treatment (28-day cycle)

• Swallow tablets whole with water; do not crush or chew

• Administer at the same time each day, with or without food

• Dose adjustments may be necessary based on blood cell counts or other side effects

• Continuous monitoring of blood counts, liver function, and kidney function is required

Possible Side Effects

Common side effects include:

• Neutropenia (low white blood cell count)

• Fatigue or weakness

• Nausea and vomiting

• Diarrhea or constipation

• Hair thinning or hair loss

• Upper respiratory infections

Serious but rare side effects may include:

• Severe neutropenia leading to infections

• Liver enzyme elevations

• Lung inflammation (pneumonitis)

• Allergic reactions

Patients should report any unusual or severe symptoms immediately to their healthcare provider.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions

• Use under strict oncologist supervision

• Regular monitoring of complete blood counts, liver, and kidney function is required

• Avoid live vaccines during treatment

• Inform your doctor of all medications, including supplements, to prevent drug interactions

• Not recommended during pregnancy or breastfeeding

Storage Instructions

• Store in a cool, dry place below 25°C

• Protect from moisture and light

• Keep tablets in the original container, tightly closed

• Keep out of reach of children.